Buy or sell DaVita stock pre IPO via an EquityZen fund
A leading provider of kidney care.
About DaVita Stock
DaVita a FORTUNE 500® company, is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of June 30, 2012, DaVita operated or provided administrative services at 1,884 outpatient dialysis centers located in the United States, serving approximately 149,000 patients. The company also operated 19 outpatient dialysis centers located in four countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu.
Senior Application Developer
Interim Chief Financial Officer & Chief Accounting Officer
Chairman and CEO
Chief Compliance Officer
Director, Strategy and Special Projects
Vice President of Clinical Affairs
Chief Operating Officer
Top Kidney Charity Directed Aid to Patients at DaVita and Fresenius Clinics, Lawsuit Claims
New York Times - Aug, 2 2019